Summary
The AI response claims numerous details about fluoxetine/Prozac weight change, appetite/cravings, and cessation effects, but the supplied FDA label excerpts only address suicidality warning/monitoring and do not contain supporting text for any of those weight-related claims. Therefore, the response cannot be verified against the provided prescribing information.
Category Scores
Accurate Statements
WARNING: suicidal thoughts and behaviors
Supported by Section 5.1, which discusses increased risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18–24) and provides close monitoring instructions, especially during early treatment and dose changes.
Unsupported Statements
Prozac (fluoxetine) can affect body weight.
No weight/appetite/food intake/cessation-related information is present in the supplied label excerpts (Sections 1, 2 (partial), 5.1, 6, 8.4).
Prozac does not affect body weight in a predictable direction for everyone.
Not supported by any provided label text.
Some people notice weight changes while taking fluoxetine.
Not supported by any provided label text.
The overall effect of fluoxetine on weight tends to be variable rather than reliably weight-gaining.
Not supported by any provided label text.
Reports of weight change with fluoxetine range from small gains to weight neutrality.
Not supported by any provided label text.
Some patients lose weight while taking fluoxetine.
Not supported by any provided label text.
Weight loss with fluoxetine can occur especially early in treatment.
Not supported by any provided label text.
The amount of weight change with fluoxetine can depend on dose.
Not supported by any provided label text.
The amount of weight change with fluoxetine can depend on how long someone has been on the medication.
Not supported by any provided label text.
Weight changes with fluoxetine can depend on whether eating habits or activity change as depression or anxiety improves.
Not supported by any provided label text.
Depression or anxiety itself can change appetite and weight.
Not supported by any provided label text.
When depression or anxiety symptoms improve, appetite can normalize.
Not supported by any provided label text.
Fluoxetine can alter appetite and cravings in some people.
Not supported by any provided label text.
Fluoxetine side effects such as nausea can affect food intake early on.
Not supported by any provided label text.
Fluoxetine-related nausea can temporarily change weight.
Not supported by any provided label text.
If weight gain is rapid or continues steadily over time, it is worth discussing with a clinician.
Not supported by any provided label text.
Weight may improve if fluoxetine is stopped.
Not supported by any provided label text.
Reversibility of weight changes after stopping fluoxetine varies.
Not supported by any provided label text.
If weight gain was driven by appetite changes as mood symptoms improved, weight may stabilize after fluoxetine is stopped.
Not supported by any provided label text.
If weight gain is due to other factors, it may persist after stopping fluoxetine.
Not supported by any provided label text.
Stopping antidepressants abruptly can cause withdrawal-like symptoms.
Not supported by any provided label text.
Stopping antidepressants abruptly can cause relapse of depression/anxiety.
Not supported by any provided label text.
Contradictions
Important Omissions
No label-grounded discussion of the boxed-warning subject matter (suicidality monitoring details such as age group 18–24, clinical worsening/unusual behavior, and timing/dose-change emphasis) appears in the provided AI weight-related claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No suicidality dosing/monitoring instructions were included in the AI's weight-focused claims; however, there is also no direct contradiction to the provided label excerpts. Most statements are unsupported because the supplied label excerpts do not address weight/cessation topics.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Nearly all claims concern weight/appetite/cessation effects that are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to labeling content present in the provided excerpts (e.g., suicidality risk and monitoring per Section 5.1). If weight-related statements are needed, provide and align them to the specific FDA label sections that describe weight/appetite/adverse reactions and discontinuation effects.